Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans.
Both thyroid hormones and irisin increase energy expenditure and induce browning of adipose tissue. However, irisin physiology and regulation remain largely unknown, and existing data are mainly derived from observational studies. In this study, we aimed to elucidate whether changes in thyroid-axis hormones alter circulating irisin levels in humans, thereby exerting a direct downstream effect on serum irisin.



Samples from a cross-sectional evaluation and two interventions were utilized, including patients who had previously undergone thyroidectomy. In the cross-sectional study, 96 consecutively enrolled subjects were divided into a euthyroid group and a subclinical hyperthyroid group, according to their serum thyrotropin (TSH) levels (TSH cutoff 0.3 mIU/L). In interventional study A, 34 patients who had undergone thyroidectomy due to thyroid cancer were withdrawn from their thyroxine replacement treatment for five weeks. In interventional study B, 13 patients underwent a recombinant human TSH stimulation protocol, and blood samples were drawn at baseline, day 3 (i.e., at least 24 hours after the second intramuscular injection), day 5, and day 10.



Irisin concentrations were not associated with thyroid-axis hormones (i.e., TSH, free thyroxine, and free triiodiothyronine) cross-sectionally in either the overall cohort or in the euthyroid and/or subclinical hyperthyroid subgroups (p > 0.05). There was no significant difference between euthyroid and subclinical hyperthyroid subjects (p = 0.60). Levothyroxine withdrawal did not result in any changes in irisin concentrations (p = 0.33). Recombinant human TSH stimulation did not induce any significant changes in circulating irisin (p = 0.60).



Changes in thyroid-axis hormone levels within the physiological or supraphysiological range do not affect circulating irisin levels in humans. Therefore, their metabolic effects are most likely independent of each other. Other regulators of irisin levels should be identified in the future.
1 Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.|2 Department of Endocrinology-Endocrine Oncology, Theagenio Cancer Hospital , Thessaloniki, Greece .
Grigorios
G
Panagiotou
2 Department of Endocrinology-Endocrine Oncology, Theagenio Cancer Hospital , Thessaloniki, Greece .
Kalliopi
K
Pazaitou-Panayiotou
1 Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.|3 Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital , Athens, Greece .
Stavroula A
SA
Paschou
1 Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.
Despina
D
Komninou
3 Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital , Athens, Greece .
Nikolaos
N
Kalogeris
3 Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital , Athens, Greece .
Andromachi
A
Vryonidou
1 Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts.|4 Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School , Boston, Massachusetts.
Christos S
CS
Mantzoros
D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000175:diagnosis; D007037:Hypothyroidism / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013963:Thyroid Hormones / Q000097:blood*
C577593:FNDC5 protein, human; D005353:Fibronectins; D013963:Thyroid Hormones